Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Antidilutive securities excluded from computation of diluted weighted shares outstanding		26,746,027	24,364,595
PAVmed Inc. 2014 Equity Plan Stock Options and Restricted Stock Awards [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		8,215,195	5,903,529
Unit Purchase Options as to Shares of Common Stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		53,000	53,000
Unit Purchase Options as to Shares Underlying Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		53,000	53,000
Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		16,814,939	16,815,039
Series W Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		381,818	381,818
Series B Convertible Preferred Stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	[1]	1,228,075	1,158,209

[1] If converted, at the election of the holder, the shares of Series B Convertible Preferred Stock issued and outstanding would result in a corresponding number of additional outstanding shares of common stock of the Company.